Acrivon Therapeutics (ACRV) Q2 2026 earnings summary

Executive summary

• Focused on precision oncology, leveraging the AP3 platform for drug discovery and development, with lead programs ACR-368 (CHK1/2 inhibitor) and ACR-2316 (WEE1/PKMYT1 inhibitor) in clinical trials targeting high unmet needs in endometrial and lung cancers.

• Advanced ACR-368 Phase 2b trial in serous endometrial cancer, with interim analysis on track for H2 2026 and Phase 3 initiation planned for H1 2027.

• ACR-2316 entered randomized dose expansion in Phase 1/2, showing favorable safety and durable single-agent activity in multiple tumor types.

• Pipeline includes internally discovered CDK11 inhibitors showing preclinical efficacy in AML, with IND filing targeted for H1 2027.

Financial highlights

• Net loss for Q2 2026 was $18.0 million, an improvement from $21.0 million in Q2 2025; net loss for the first half of 2026 was $37.0 million, down from $40.7 million year-over-year.

• Operating expenses for Q2 2026 were $18.7 million, down from $22.6 million in Q2 2025, driven by lower R&D and G&A costs.

• Research and development expenses decreased to $13.8 million from $16.2 million year-over-year, mainly due to non-recurring 2025 milestones and program timing.

• General and administrative expenses fell to $4.8 million from $6.5 million, primarily due to lower employee-related costs.

• Cash, cash equivalents, and investments totaled $90.0 million as of June 30, 2026, expected to fund operations into Q4 2027.

Outlook and guidance

• Existing cash and investments expected to fund operations into Q4 2027.

• Interim analysis and data update for ACR-368 Phase 2b all-comer serous EC arms expected in H2 2026.

• Phase 3 confirmatory trial for ACR-368 planned for H1 2027.

• IND filing for CDK11 inhibitor candidate anticipated in H1 2027.

• Anticipates continued operating losses as clinical and preclinical programs advance; additional funding will be required for future growth and development.